If we unraveled the DNA of the 46 chromosomes of a single human cell, it would barely measure 2 meters. If we did the same with the rest of the body, if we aligned the 3 billion base pairs of its 5 trillion cells, we could travel the distance from the Earth to the Sun more than 100 times. It seems unreachable. However, that is the unit of knowledge of the large sequencing projects achieved in 2023. From the generation of the human pangenome to cell-by-cell maps of the brain and kidneys, scientists this year have completed several omics collaborative projects stored in large international databases. Now, what’s the plan? Read More
Dysregulation of the kallikrein-kinin system (KKS) is involved in hereditary angioedema (HA) pathophysiology; thus, the inhibition of factor XIIa (FXIIa), a central mediator of angioedema and initiator of KKS, is a therapeutic strategy to prevent and treat HA attacks. Read More
Enveric Biosciences Inc. has named EB-003 as its lead drug candidate from the company’s next-generation EVM301 series. EB-003 was selected based on data analyses suggesting the molecule’s potential to be a first-in-class approach to addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. Read More
Researchers from Banasthali University and Central Drug Research Institute (CDRI) have reported the discovery of novel antimalaria candidates. Read More
Palisade Bio Inc.’s co-development partner Giiant Pharma Inc. has received the second milestone payment of a grant for inflammatory bowel disease. Read More
Researchers from Hibercell Inc. recently presented preclinical data for HC-7366, a first-in-class direct activator of GCN2 (general control nonderepressible 2) currently in phase I development for the treatment of solid tumors (NCT05121948). Read More
Janssen R&D (Ireland) has identified compounds acting as viral fusion inhibitors and reported to be useful for the treatment of respiratory syncytial virus (RSV) infections. Read More
Work at Zhuhai Yufan Biotechnologies Co. Ltd. has led to the development of proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety coupled to eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)-targeting moiety. Read More
Chimeric antigen receptor (CAR) therapies targeted against CD19 have been widely used for the treatment of B-cell malignancies. However, the down-regulation of CD19 can lead to relapse, and autologous CAR T therapies have limitations that need to be addressed. Read More
Biocells (Beijing) Biotech Co. Ltd. has patented isoquinolinone derivatives acting aquaporin-4 (AQP4) inhibitors and thus reported to be useful for the treatment of hypervolemia (fluid overload) and cerebral ischemia. Read More
Kinoteck Therapeutics Co. Ltd. have prepared and tested new ribosomal protein S6 kinase alpha-3 (RSK-2; MAPKAPK-1b) inhibitors potentially useful for the treatment of cancer. Read More
Researchers from Epics Therapeutics SA presented preclinical data for EP-102, a novel small-molecule inhibitor of N6-adenosine-methyltransferase catalytic subunit (METTL3), being developed for the treatment of cancer. Read More
Are you trying to stay on top of developments in CAR T therapies? Drug resistance? Emerging compounds? Updates from certain regulatory agencies? Want to be the first to learn about new biomarkers or business deals? You can still find these articles in the daily BioWorld e-newsletters or on the website, but if you’re laser-focused on a specific topic, we have a way to highlight the news you need as it happens, whether we’ve published a full-length feature story or a brief update. You asked and we listened. Now, in addition to the daily news lineup, you can create topic alerts to be delivered directly to your inbox or via an RSS reader. It’s easy to set up. Instructions can be found here: https://www.bioworld.com/featured-feeds. Happy holidays! Read More
